BACKGROUND: Increased matrix metalloproteinase (MMP) 9 activity has been implicated in the formation of abdominal aortic aneurysm (AAA). The aim was to explore the association between potentially functional variants of the MMP-9 gene and AAA. METHODS: The -1562C > T and -1811A > T variants of the MMP-9 gene were genotyped in 678 men with an AAA (at least 30 mm in diameter) and 659 control subjects (aortic diameter 19-22 mm) recruited from a population-based trial of screening for AAA. Levels of MMP-9 were measured in a random subset of 300 cases and 84 controls. The association between genetic variants (including haplotypes) and AAA was assessed by multivariable logistic regression. RESULTS: There was no association between the MMP-9-1562C > T (odds ratio (OR) 0.70 (95 per cent confidence interval (c.i.) 0.27 to 1.82)) or -1811A > T (OR 0.71 (95 per cent c.i. 0.28 to 1.85)) genotypes, or the most common haplotype (OR 0.81 (95 per cent c.i. 0.62 to 1.05)) and AAA. The serum MMP-9 concentration was higher in cases than controls, and in minor allele carriers in cases and controls, although the differences were not statistically significant. CONCLUSION: In this study, the genetic tendency to higher levels of circulating MMP-9 was not associated with AAA.
BACKGROUND: Increased matrix metalloproteinase (MMP) 9 activity has been implicated in the formation of abdominal aortic aneurysm (AAA). The aim was to explore the association between potentially functional variants of the MMP-9 gene and AAA. METHODS: The -1562C > T and -1811A > T variants of the MMP-9 gene were genotyped in 678 men with an AAA (at least 30 mm in diameter) and 659 control subjects (aortic diameter 19-22 mm) recruited from a population-based trial of screening for AAA. Levels of MMP-9 were measured in a random subset of 300 cases and 84 controls. The association between genetic variants (including haplotypes) and AAA was assessed by multivariable logistic regression. RESULTS: There was no association between the MMP-9-1562C > T (odds ratio (OR) 0.70 (95 per cent confidence interval (c.i.) 0.27 to 1.82)) or -1811A > T (OR 0.71 (95 per cent c.i. 0.28 to 1.85)) genotypes, or the most common haplotype (OR 0.81 (95 per cent c.i. 0.62 to 1.05)) and AAA. The serum MMP-9 concentration was higher in cases than controls, and in minor allele carriers in cases and controls, although the differences were not statistically significant. CONCLUSION: In this study, the genetic tendency to higher levels of circulating MMP-9 was not associated with AAA.
Authors: D M Hovsepian; S J Ziporin; M K Sakurai; J K Lee; J A Curci; R W Thompson Journal: J Vasc Interv Radiol Date: 2000 Nov-Dec Impact factor: 3.464
Authors: W Richard W Wilson; Marcus Anderton; Edward C Schwalbe; J Louise Jones; Peter N Furness; Peter R F Bell; Matthew M Thompson Journal: Circulation Date: 2006-01-24 Impact factor: 29.690
Authors: G Sangiorgi; R D'Averio; A Mauriello; M Bondio; M Pontillo; S Castelvecchio; S Trimarchi; V Tolva; G Nano; V Rampoldi; L G Spagnoli; L Inglese Journal: Circulation Date: 2001-09-18 Impact factor: 29.690
Authors: R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson Journal: J Clin Invest Date: 2000-06 Impact factor: 14.808
Authors: K Jamrozik; P E Norman; C A Spencer; R W Parsons; R Tuohy; M M Lawrence-Brown; J A Dickinson Journal: Med J Aust Date: 2000-10-02 Impact factor: 7.738
Authors: David R Lorelli; Jessie M Jean-Claude; Christopher J Fox; Jason Clyne; Robert A Cambria; Gary R Seabrook; Jonathan B Towne Journal: J Vasc Surg Date: 2002-05 Impact factor: 4.268
Authors: Gregory T Jones; Victoria L Phillips; Eugenie L Harris; Jeremy I Rossaak; André M van Rij Journal: J Vasc Surg Date: 2003-12 Impact factor: 4.268
Authors: Gorav Ailawadi; Brian S Knipp; Guanyi Lu; Karen J Roelofs; John W Ford; Kevin K Hannawa; Keith Bishop; Porama Thanaporn; Peter K Henke; James C Stanley; Gilbert R Upchurch Journal: J Vasc Surg Date: 2003-05 Impact factor: 4.268
Authors: Craig D Ferguson; Paula Clancy; Bernard Bourke; Philip J Walker; Anthony Dear; Tim Buckenham; Paul Norman; Jonathan Golledge Journal: Am Heart J Date: 2010-02 Impact factor: 4.749
Authors: A F Baas; J Medic; R van 't Slot; C G de Kovel; A Zhernakova; R H Geelkerken; S E Kranendonk; S M van Sterkenburg; D E Grobbee; A P Boll; C Wijmenga; J D Blankensteijn; Y M Ruigrok Journal: Eur J Hum Genet Date: 2009-08-12 Impact factor: 4.246
Authors: Sophie E Rowbotham; Jenna L Pinchbeck; Georgina Anderson; Bernie Bourke; Michael Bourke; T Christian Gasser; Rene Jaeggi; Jason S Jenkins; Corey S Moran; Susan K Morton; Christopher M Reid; Ramesh Velu; Lisan Yip; Joseph V Moxon; Jonathan Golledge Journal: Trials Date: 2017-11-16 Impact factor: 2.279